Selexipag
【Chemical Name】Selexipag
【Original】Actelion
【Time to market】2015.12.21
【Patents expire】2023.04.04
【Dosage and Usage】Tablets: 200 mcg, 400 mcg, 600 mcg, 800 mcg, 1000 mcg,
1200 mcg, 1400 mcg, 1600 mcg. For Injection: 1800 mcg of selexipag.used for
the treatment of pulmonary arterial hypertension (PAH, WHO Group I)
Selexipag
一、 Product Overview
Selexipag, used to treat pulmonary arterial hypertension (PAH), was originally developed by Nippon neopharmaceutics and later licensed to actel for co-development. On December 21, 2015, it was approved by the food and drug administration (FDA) and the patent of the compound expired on April 4, 2023.
二、Main products
Description | Structural Formula | CAS No. | Category |
Selexipag |  | 475086-01-2 | API |
4-(Isopropylamino)butanol |  | 42042-71-7 | intermediates |
4-[(5,6-diphenyl-2-pyrazinyl)(1-methylethyl)amino]-1-Butanol |  | 475086-75-0 | intermediates |
5-chloro-2,3-diphenylpyrazine |  | 41270-66-0 | intermediates |
Note: Products protected by valid patents are not offered for sale in countries where the sale of such products constitutes patent infringement and its liability is at buyer's risk.